Neoprobe on the Rise

M.E. Garza submits:

By Patrick Crutcher

Shares of Neoprobe (NEOP.OB) rose from $3 to a high of $3.71 on Wednesday after the company announced on Monday that they had been approved to list their shares on the NYSE AMEX. Neoprobe had been trading on the OTC Bulletin Board, but will now trade on the NYSE Amex on Thursday, February 10, 2011.

As we told premium subscribers on Monday, Neoprobe's ticker symbol will change to “NEOP” from “OTCBB:NEOP”. This development is a significant milestone in their history and should attract the interest of more investors, specifically institutional ones. When shares were trading at $2.15 we told our readers that pivotal catalysts will shape the company this year. We continue to believe that management has executed well on their promises and there is more potential upside in the coming months.

President and CEO David C. Bupp noted that the,“Enhanced investor visibility will be important to our ongoing business strategy and to building shareholder value as Neoprobe achieves upcoming development and commercial milestones, including completion of enrollment in our Lymphoseek NEO3-09 Phase 3 clinical study conducted in subjects with breast cancer or melanoma, disclosure of the NEO3-09 clinical study data, the filing of our Lymphoseek NDA, the completion of our FDA pre-IND meeting for RIGScan, and additional progress milestones on RIGScan development. We believe this sequential line-up of achievements over the coming months represents important progress and will continue to add value for the Company and its shareholders.”

Management has put their money where there mouth

Complete Story »

Amerie Rachel Bilson Karen Carreno Bijou Phillips Marika Dominczyk